Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sunil Shah | M | 51 |
Alevin Therapeutics Ltd.
 Alevin Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Alevin Therapeutics Ltd. is a British company that focuses on developing safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company is based in Cambridge, UK and was founded in 2022 by Chris Moody, Thomas McInally, Alison John. The company's preclinical pipeline features small molecules that target integrin receptors. | - |
| Alice Laura MacGowan | M | 48 |
Alevin Therapeutics Ltd.
Alevin Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Alevin Therapeutics Ltd. is a British company that focuses on developing safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company is based in Cambridge, UK and was founded in 2022 by Chris Moody, Thomas McInally, Alison John. The company's preclinical pipeline features small molecules that target integrin receptors. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Chris Moody | M | - |
Alevin Therapeutics Ltd.
Alevin Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Alevin Therapeutics Ltd. is a British company that focuses on developing safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company is based in Cambridge, UK and was founded in 2022 by Chris Moody, Thomas McInally, Alison John. The company's preclinical pipeline features small molecules that target integrin receptors. | - |
| Alison John | F | - |
Alevin Therapeutics Ltd.
Alevin Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Alevin Therapeutics Ltd. is a British company that focuses on developing safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies. The company is based in Cambridge, UK and was founded in 2022 by Chris Moody, Thomas McInally, Alison John. The company's preclinical pipeline features small molecules that target integrin receptors. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thomas McInally
- Personal Network
